605 related articles for article (PubMed ID: 24908630)
1. The PD-1/PD-Ls pathway and autoimmune diseases.
Dai S; Jia R; Zhang X; Fang Q; Huang L
Cell Immunol; 2014 Jul; 290(1):72-9. PubMed ID: 24908630
[TBL] [Abstract][Full Text] [Related]
2. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
Fife BT; Bluestone JA
Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-Ls pathways between CD4(+) T cells and pleural mesothelial cells in human tuberculous pleurisy.
Yin W; Tong ZH; Cui A; Zhang JC; Ye ZJ; Yuan ML; Zhou Q; Shi HZ
Tuberculosis (Edinb); 2014 Mar; 94(2):131-9. PubMed ID: 24406080
[TBL] [Abstract][Full Text] [Related]
4. Altered availability of PD-1/PD ligands is associated with the failure to control autoimmunity in NOD mice.
Yadav D; Hill N; Yagita H; Azuma M; Sarvetnick N
Cell Immunol; 2009; 258(2):161-71. PubMed ID: 19497561
[TBL] [Abstract][Full Text] [Related]
5. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.
Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR
Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease.
Fujiwara H; Maeda Y; Kobayashi K; Nishimori H; Matsuoka K; Fujii N; Kondo E; Tanaka T; Chen L; Azuma M; Yagita H; Tanimoto M
J Immunol; 2014 Sep; 193(5):2565-73. PubMed ID: 25080485
[TBL] [Abstract][Full Text] [Related]
7. Biochemical signaling of PD-1 on T cells and its functional implications.
Boussiotis VA; Chatterjee P; Li L
Cancer J; 2014; 20(4):265-71. PubMed ID: 25098287
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L pathway and autoimmunity.
Okazaki T; Wang J
Autoimmunity; 2005 Aug; 38(5):353-7. PubMed ID: 16227150
[TBL] [Abstract][Full Text] [Related]
9. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity.
Gianchecchi E; Delfino DV; Fierabracci A
Autoimmun Rev; 2013 Sep; 12(11):1091-100. PubMed ID: 23792703
[TBL] [Abstract][Full Text] [Related]
10. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation.
Kuipers H; Muskens F; Willart M; Hijdra D; van Assema FB; Coyle AJ; Hoogsteden HC; Lambrecht BN
Eur J Immunol; 2006 Sep; 36(9):2472-82. PubMed ID: 16917960
[TBL] [Abstract][Full Text] [Related]
11. Antibodies against B7-DC with differential binding properties exert opposite effects.
Ritprajak P; Hashiguchi M; Akiba H; Yagita H; Okumura K; Azuma M
Hybridoma (Larchmt); 2012 Feb; 31(1):40-7. PubMed ID: 22316484
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of programmed death ligand 1 in dendritic cells inhibits allogeneic lymphocyte activation in mice.
Li W; Wang X; Chen R; Zhu H; Chen G; Sun X
J Surg Res; 2012 Aug; 176(2):e79-87. PubMed ID: 22381170
[TBL] [Abstract][Full Text] [Related]
13. B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway.
Herold M; Posevitz V; Chudyka D; Hucke S; Groß C; Kurth F; Leder C; Loser K; Kurts C; Knolle P; Klotz L; Wiendl H
J Immunol; 2015 Oct; 195(8):3584-95. PubMed ID: 26378076
[TBL] [Abstract][Full Text] [Related]
14. Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade.
Pauken KE; Nelson CE; Martinov T; Spanier JA; Heffernan JR; Sahli NL; Quarnstrom CF; Osum KC; Schenkel JM; Jenkins MK; Blazar BR; Vezys V; Fife BT
J Immunol; 2015 Apr; 194(8):3551-3555. PubMed ID: 25769925
[TBL] [Abstract][Full Text] [Related]
15. T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands.
Karasar P; Esendagli G
Breast Cancer Res Treat; 2014 Jun; 145(3):605-14. PubMed ID: 24816762
[TBL] [Abstract][Full Text] [Related]
16. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.
Salomon B; Bluestone JA
Annu Rev Immunol; 2001; 19():225-52. PubMed ID: 11244036
[TBL] [Abstract][Full Text] [Related]
17. Critical co-stimulatory pathways in the stability of Foxp3+ Treg cell homeostasis in Type I diabetes.
Kornete M; Piccirillo CA
Autoimmun Rev; 2011 Dec; 11(2):104-11. PubMed ID: 21875694
[TBL] [Abstract][Full Text] [Related]
18. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.
Carreno BM; Collins M
Annu Rev Immunol; 2002; 20():29-53. PubMed ID: 11861596
[TBL] [Abstract][Full Text] [Related]
19. Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases.
Ibañez-Vega J; Vilchez C; Jimenez K; Guevara C; Burgos PI; Naves R
J Autoimmun; 2021 Sep; 123():102702. PubMed ID: 34311143
[TBL] [Abstract][Full Text] [Related]
20. The B7 family revisited.
Greenwald RJ; Freeman GJ; Sharpe AH
Annu Rev Immunol; 2005; 23():515-48. PubMed ID: 15771580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
